- Home
- RXRX
as 12-18-2024 12:42pm EST
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 2.6B | IPO Year: | 2021 |
| Target Price: | $9.25 | AVG Volume (30 days): | 15.4M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.60 - $15.74 | Next Earning Date: | 11-06-2024 |
| Revenue: | $65,184,000 | Revenue Growth: | 37.64% |
| Revenue Growth (this year): | 60.17% | Revenue Growth (next year): | 19.88% |
Stock Insider Trading Activity of Recursion Pharmaceuticals Inc. (RXRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gibson Christopher | RXRX | Chief Executive Officer | Dec 4 '24 | Sell | $7.14 | 40,000 | $285,600.00 | 736,633 | |
| Gibson Christopher | RXRX | Chief Executive Officer | Nov 13 '24 | Sell | $7.55 | 40,000 | $301,800.00 | 736,633 | |
| Borgeson Blake | RXRX | Director | Nov 12 '24 | Sell | $7.64 | 11,447 | $87,457.37 | 7,066,113 | |
| Secora Michael | RXRX | Chief Financial Officer | Nov 12 '24 | Sell | $7.65 | 30,000 | $229,504.50 | 1,475,256 | |
| Borgeson Blake | RXRX | Director | Oct 29 '24 | Sell | $6.72 | 11,447 | $76,926.13 | 7,066,113 | |
| Marriott Tina | RXRX | President and COO | Oct 24 '24 | Sell | $6.31 | 6,000 | $37,854.60 | 521,138 | |
| Borgeson Blake | RXRX | Director | Oct 15 '24 | Sell | $6.67 | 11,447 | $76,326.31 | 7,066,113 | |
| Secora Michael | RXRX | Chief Financial Officer | Oct 8 '24 | Sell | $6.34 | 30,000 | $190,131.00 | 1,475,256 | |
| Gibson Christopher | RXRX | Chief Executive Officer | Oct 2 '24 | Sell | $6.12 | 40,000 | $244,800.00 | 736,633 | |
| Borgeson Blake | RXRX | Director | Oct 1 '24 | Sell | $6.22 | 11,447 | $71,149.97 | 7,066,113 |
Latest Recursion Pharmaceuticals Inc. News
RXRX Breaking Stock News: Dive into RXRX Ticker-Specific Updates for Smart Investing
Insider Monkey
3 days ago
Jim Cramer Says He Was Wrong on NVIDIA Holding Recursion Pharmaceuticals (RXRX)
Insider Monkey
6 days ago
Recursion Pharmaceuticals’ (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials
Insider Monkey
7 days ago
Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers
MT Newswires
8 days ago
Recursion Pharmaceuticals Says Potential Advanced Solid Tumor Treatment Well Tolerated
GlobeNewswire
9 days ago
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
MT Newswires
12 days ago
Recursion Pharmaceuticals Insider Sold Shares Worth $285,600, According to a Recent SEC Filing
Insider Monkey
14 days ago
Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘It Is Worthwhile Speculation’
GlobeNewswire
15 days ago
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
Compare RXRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RXRX Recursion Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.